Convalife (Shanghai) Co., Ltd.

Quick facts

Phase 2 pipeline

• CVL237 tablets · Diabetes
  CVL237 tablets are a small molecule that targets the SGLT2 receptor.
• Neratinib tablets

Phase 1 pipeline

• CVL006 in combination with DS-8201
• CVL006 in combination with SKB264

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Convalife (Shanghai) Co., Ltd. portfolio CI brief
• Convalife (Shanghai) Co., Ltd. pipeline updates RSS